Legend Biotech CEO Ingrid Zhang Receives 1.13M RSU Award

What Happened
Ingrid Zhang, CEO of Legend Biotech (LEGN), was granted 1,131,860 restricted share units (RSUs) on September 15, 2026. The award is reported as an acquisition at $0.00 per share (no cash paid). This is an equity grant (award), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-09-15; Form 4 filed: 2026-09-16 (appears timely).
• Transaction type: Grant / Award (code A); amount: 1,131,860 RSUs; reported price: $0.00; total cash value reported: $0.
• Shares owned after transaction: not disclosed in this filing.
• Footnote F2: These are restricted share units (each RSU is a contingent right to one ordinary share). Vesting: 1/3 vests on each of Sept 15, 2027, 2028 and 2029, subject to continued service.
• Footnote F1: Ordinary shares may be represented by ADSs; each ADS = 2 ordinary shares.
• No 10b5-1 plan, tax withholding, or sale reported in this filing—this is a standard executive grant.

Context
RSUs are a deferred equity award: they do not convert to shares (and are not freely tradable) until they vest and are settled. Executive RSU grants are common for compensation and retention; because these are contingent and vest over three years, they do not represent an immediate purchase or sale of stock.